12 July, 2021
Orient Pharma announced on 9 July a licensing agreement with Jingxin Pharmaceutical based in Zhejiang, China, for production and sales of the company’s cholesterol medication. The later will pay up to TWD120m royalty for the licensing, product development and sales to Orient Pharma, as well as sharing profits gained from the medication.
The licensing agreement will strengthen Orient Pharma’s foothold in China so as to enhance product suite of Jingxin Pharmaceutical for anti-hypercholesterolemia drugs, such as Simvastatin tables and Pitavastatin calcium dispersible tables. Data suggests that one third of the population over 35 years of age in China are at risk of Abnormal Cholesterol (Dyslipidemia).
Jingxin Pharmaceutical is publicly listed in China, having a strong presence in pharmaceutical R&D, manufacturing and product sales. The company will be able to take cholesterol medication by Orient Pharma to market in China and deliver strategic objectives with us down the line, said Orient Pharma.
The agreement, according to Jingxin, will have a positive impact on Jingxin’s cardiovascular product rollout in China. Jingxin has been dedicating to drug development in psycho-neurological and cardiovascular fields.
A phase 3 study regarding this new cholesterol-lowering medication is being conducted in Australia, New Zealand and Taiwan, which will be completed in the second half of the year. The new drug is a combination of two different cholesterol medications using Microgranules- a technology by Orient Pharma, it is expected to be more effective than one single drug in terms of controlling low-density cholesterol (LDL-C) and total cholesterol (TC). The combination built-in with Microgranules will reduce the need for patients taking several medications at a time, improving drug compliance whilst lowering the risk of cardiovascular disease.
Source in Chinese: Economic Daily